PDCD1 and classic Hodgkin lymphoma: In the third hypothesis (iii), we presume that any protein of SARS-CoV-2 may bind to PD-1, similar to the targeted mAb drugs pembrolizumab or nivolumab, and induce remission of cHL/FL.